GlassScriptPhysician profile
Kimberly G Orr
NPI 1043611734
$7,757.43
in general payments reported to CMS, 2019-2025
20 companies · $3,006 in 2025
The $3,006 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $189 · 2021: $379 · 2022: $417 · 2023: $1,176 · 2024: $637 · 2025: $3,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753 · Travel and Lodging: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.02 |
| Travel and Lodging | $1,065.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,831.20 | 2019-2021 | |
| Biotissue Holdings INC. | $1,491.59 | 2025 | |
| Alcon Vision LLC | $1,196.32 | 2019-2025 | Precision7, Precision 1, Wavelight Sightmap |
| Bausch & Lomb Americas INC. | $963.46 | 2022-2025 | Infuse, Infuse Multifocal, Miebo |
| Sun Pharmaceutical Industries INC. | $479.37 | 2019-2025 | Cequa |
| Coopervision INC. | $413.30 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $323.90 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $181.57 | 2023-2025 | Acuvue |
| Allergan, INC. | $133.21 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $122.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.58 | 2019-2022 | |
| Oyster Point Pharma, INC. | $97.69 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $94.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $59.21 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $56.99 | 2025 | Photrexa Viscous and Photrexa |
| Abbvie INC. | $50.27 | 2023-2024 | |
| Dompe US, INC. | $42.88 | 2025 | Oxervate |
| Harrow Eye, LLC | $30.37 | 2025 | Vevye |
| Thea Pharma INC. | $21.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.